Article Text

Download PDFPDF
Journal club summaries
What’s hot that the other lot got
  1. Andrew C Kidd1,2
  1. 1 Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
  2. 2 Glasgow Pleural Disease Unit, Queen Elizabeth University Hospital, Glasgow, UK
  1. Correspondence to Dr Andrew C Kidd, University of Glasgow, Glasgow G12 8QQ, UK; andrew.kidd{at}

Statistics from

Stemming the flow: nebulised transexamic acid can be used to control bleeding in patients with non-massive haemoptysis

Transexamic acid (TA) is an antifibrinolytic drug used to control bleeding and is most commonly administered as a systemic preparation. The effectiveness of nebulised TA in the treatment of haemodynamically stable patients with non-massive haemoptysis was assessed in a prospective, double-blind, randomised controlled trial of nebulised TA (500 mg, three times per day) versus 0.9% 5 mL normal saline (Wand et al, Chest 2018; doi: 10.1016/j.chest.2018.09.026). Forty-seven patients were randomised; 25 patients received nebulised TA and 22 patients received the normal saline placebo. Resolution of bleeding was achieved within 5 days from admission in 96% of the TA-treated group and 50% of the placebo group (p<0.0005). Mean hospital length of stay was shorter for the TA group compared with the placebo group (5.7±2.5 versus 7.8±4.6 days, p=0.046). Four out of 22 patients in the placebo group and none out of 25 patients in the TA group required interventional procedures to control bleeding (p=0.041). There were no serious adverse events reported in …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.